Treatment Overview
The “PGT-M Carrier Screening Plus” program combines two key fertility-genetic services: first, carrier screening to determine whether one or both partners carry gene variants that could cause inherited monogenic disorders; secondly, preimplantation genetic testing for monogenic disorders (PGT-M) within an IVF cycle to ensure embryos produced are free from those specific inherited gene mutations. In Korea, top fertility centres integrate comprehensive carrier panels (hundreds of genes via next-generation sequencing) with tailored PGT-M workflows, advanced embryo biopsy, and high-quality genomic labs. This dual approach offers heightened reproductive assurance and tailored embryo selection for couples at genetic risk.
Purpose & Benefits
The purpose of this program is to provide couples with maximum genetic insight and embryo selection precision—reducing the risk of transmitting serious inherited single-gene disorders, and enhancing the likelihood of a healthy pregnancy.
Key benefits include:
- Early identification of carrier status in one or both partners, enabling informed decision-making before IVF.
- Customized PGT-M testing aligned to the exact gene variant(s) found in the couple, thus maximizing accuracy of embryo screening.
- Prevention of transmission of monogenic disorders (e.g., thalassemia, cystic fibrosis, spinal muscular atrophy) to offspring.
- Integration with IVF embryo assessment, so only embryos unaffected by the identified mutation(s) are transferred.
- Greater peace of mind for couples with known genetic backgrounds or family history of inherited conditions.
- Optimized IVF outcomes by combining genetic assurance with embryo quality and morphology.
- Allows single-embryo transfer with higher confidence in genetic health, reducing risks of multiple pregnancies.
Korean centres offering this program are well-equipped for high-precision genomic assays, embryo biopsy, and follow-up genetic counselling.
Ideal Candidates
This program is especially suited to:
- Couples where one or both partners are known carriers of a single-gene mutation.
- Couples with a family history of monogenic disorders (e.g., muscular dystrophy, hemophilia, thalassemia, cystic fibrosis).
- Patients who have had prior children or pregnancy outcomes affected by single-gene disorders.
- Couples planning IVF who want to minimize genetic risks in offspring.
- Patients using donor gametes or considering donor embryos and wishing full genetic assurance.
- Cancer survivors or patients whose fertility is being preserved but wish to prevent inherited disorders in future use of stored embryos.
- International patients seeking high-standard genetic IVF services with carrier screening and PGT-M in one destination.
Possible Risks & Complications
While the PGT-M Carrier Screening Plus program offers high benefit, some risks and limitations should be acknowledged:
- Embryo biopsy (trophectoderm cell removal) carries a very small risk of affecting embryo viability, though rare with expert labs.
- Mosaicism: some embryos may exhibit a mixture of normal and abnormal cells, complicating results interpretation.
- Limitations of PGT-M: Only known gene variants are tested; unknown mutations cannot be screened.
- Emotional/ethical stress: Couples may face difficult decisions if usable unaffected embryos are few or none.
- Cost: The combined carrier screening + PGT-M + IVF costs represent a significant investment.
- Time: Genetic testing, counselling, and customized assay design may add time to the IVF cycle.
- No absolute guarantee: While testing reduces risk, it cannot eliminate all genetic or development issues.
High-quality Korean labs mitigate these risks by using meticulous biopsy protocols, advanced sequencing, rigorous quality control, and full genetic counselling.
Techniques & Laboratory Methods
Korean fertility centres running this program typically use the following methods:
- Carrier Screening Panel (NGS-based): Both partners are tested for hundreds of genes using next-generation sequencing to identify carrier status. Korean labs deliver high-precision panels and informed reports.
- Customized PGT-M Assay Design: Once a pathogenic variant is identified, a targeted embryo screening assay is developed to detect that exact mutation in biopsied cells.
- Whole Genome Amplification (WGA): Cells removed from embryos are amplified to generate sufficient DNA for accurate testing.
- Trophectoderm Biopsy (Day 5–6 Blastocyst): Specialized micro‐tools and lasers are used to sample outer cells of the embryo without harming the inner cell mass.
- Next-Generation Sequencing (NGS) / Targeted Gene Panel Analysis: Embryo DNA is analysed for the specific mutation(s) identified in parents, as well as often screened for aneuploidy (PGT-A) concurrently.
- Bioinformatic & Genetic Counselling Integration: Results are interpreted by embryologists, geneticists and fertility physicians together; counselling is offered before and after results.
- Vitrification & Embryo Storage: Biopsied embryos are frozen while awaiting results; only unaffected embryos are then transferred.
- International-Patient and Multilingual Support: Many Korean clinics support English language and international logistics.
Recovery & Aftercare
From the patient’s perspective, the workflow overlaps with standard IVF, with additional genetic consultation:
- After ovarian stimulation and egg retrieval, fertilisation (often via ICSI) occurs.
- Embryos cultured to blastocyst stage; biopsy performed; embryos vitrified while awaiting results.
- Genetic counselling session held to review carrier screening results and embryo genetic testing outcomes.
- Once unaffected embryos are identified, a frozen embryo transfer (FET) is scheduled.
- Post-transfer monitoring (hCG, ultrasound) follows usual IVF protocols.
- Long-term follow-up may include prenatal genetic testing (amniocentesis or NIPT) as additional confirmation if desired.
- Emotional/psychological support is provided as part of holistic care, particularly when genetic results impact decision-making.
Korean centres emphasize patient communication, transparency of genetic findings, and continuity of care through each step.
Results & Longevity
The combination of carrier screening + PGT-M in Korean IVF programs demonstrates strong reproductive value:
- High probability of selecting embryos free from known monogenic disorders, thus significantly reducing risk of disease transmission.
- Integration with IVF improves live-birth outcomes by selecting genetically optimal embryos and avoiding transfers with high-risk embryos.
- Enhanced confidence in embryo quality supports safe single‐embryo transfer strategies.
- Internationally competitive success rates thanks to advanced laboratories and stringent protocols.
- Long-term health data of children born following PGT-M programs show similar development and outcomes to naturally conceived peers (in well-selected cohorts).
- For couples requiring donor gametes, the genetic screening adds a layered safety measure to ensure healthy offspring.
While specific national statistics for Korea may be limited, many leading clinics document high success, low risk, and premium care experiences.
Treatment Process in Korea
Step 1 – Initial Consultation & Carrier Screening
- Both partners undergo genetic counselling and carrier screening (blood or saliva).
- Identification of any pathogenic gene variants and discussion of PGT-M need.
Step 2 – IVF Protocol & Egg Retrieval
- Ovarian stimulation tailored to patient; egg retrieval scheduled.
- Fertilisation (ICSI) and embryo culture to blastocyst.
Step 3 – Embryo Biopsy & Genetic Testing
- Trophectoderm biopsy performed on day 5/6.
- Biopsied cells undergo customized PGT-M assay (and often PGT-A).
- Embryos vitrified while awaiting results.
Step 4 – Genetic Counselling & Embryo Selection
- Geneticists review results; embryos classified as “unaffected” vs “affected/at risk”.
- The highest-quality unaffected embryo(s) selected for transfer.
Step 5 – Embryo Transfer & Follow-Up
- Frozen embryo transfer in hormonally prepared cycle.
- Pregnancy monitoring, prenatal genetic screening offered.
- Cryostorage of remaining unaffected embryos for future use.
Why Korea is a Top Destination
- Advanced genomic and embryology labs with high accuracy and turnaround.
- Strong track record in PGT programs and international patient support.
- Transparent pricing, multilingual support, and integrated fertility-genetics services. Koreabeauty
- High standards of care, certifications, and technology investment in reproductive medicine.
Cost Range
Estimated cost for the program in Korea:
- Carrier screening panel (both partners): USD 800 – USD 1,500 each (depending on number of genes)
- Customized PGT-M assay + embryo biopsy + genetic testing: USD 4,000 – USD 7,000
- IVF cycle + egg retrieval + embryo culture + vitrification: USD 6,000 – USD 10,000 (varies by clinic and patient factors)
- Frozen embryo transfer (FET): USD 2,000 – USD 4,000
- Annual embryo storage: USD 300 – USD 700
Overall package (carrier screening + IVF + PGT-M + FET) could range approximately USD 10,000 – USD 15,000 or more, depending on complexity and number of embryos.
Popular Clinics in Korea
- CHA Fertility Center – Seoul Station – Offers comprehensive PGT-M and genetic services alongside IVF.
- Hamchoon Women’s Clinic – Known for infertility genetics and dedicated labs.
- M Fertility Center – Offers personalized IVF services with genetic screening.
